SCN4A
Sodium channel protein type 4 subunit alpha
As of the edition of 20 October 2026, SCN4A (sodium channel protein type 4 subunit alpha, UniProt P35499) has 57 drugs tested at it and 23 companies on the list, 1 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35499
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Nervous system; Mental health; Injuries; Bones, joints and muscles; Cancer; Heart and blood vessels; Urinary and reproductive; Nutrition and metabolism
- Registered trials of its drugs
- 3,731
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 47 |
| Active | 3 |
| Went quiet | 6 |
| Withdrawn from market | 1 |
| Total | 57 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bupivacaine | Marketed | Phase 4 | none listed |
| Lidocaine | Marketed | Phase 4 | none listed |
| Ropivacaine | Marketed | Phase 4 | none listed |
| Topiramate | Marketed | Phase 4 | none listed |
| Lamotrigine | Marketed | Phase 4 | none listed |
| Carbamazepine | Marketed | Phase 4 | none listed |
| Lacosamide | Marketed | Phase 4 | Ended 2026 |
| Levobupivacaine | Marketed | Phase 4 | none listed |
| Riluzole | Marketed | Phase 4 | none listed |
| Tetracaine | Marketed | Phase 4 | none listed |
| Eslicarbazepine acetate | Marketed | Phase 4 | Ended 2026 |
| Ranolazine | Marketed | Phase 4 | none listed |
12 of 57 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 7 |
| Engaged | 12 |
| Undetermined | 3 |
| Total on the list | 23 |
The other 20 companies at SCN4A
In the product23 companies in all; 20 are not named here, and no score is.
See the 23 companies at SCN4A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.